NASDAQ:ELGX - Endologix Stock Price, Forecast & News

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

Shares of Endologix reverse split before market open on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

Endologix, Inc. (NASDAQ:ELGX) announced its earnings results on Wednesday, February, 19th. The medical instruments supplier reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.70) by $0.28. The medical instruments supplier had revenue of $35.75 million for the quarter, compared to analysts' expectations of $35.80 million. Endologix had a negative net margin of 45.17% and a negative return on equity of 68.69%. View Endologix's Earnings History.

Endologix is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Endologix.

Endologix updated its FY 2020 After-Hours earnings guidance on Wednesday, February, 19th. The company provided EPS guidance of for the period. The company issued revenue guidance of $145 million, compared to the consensus revenue estimate of $150.02 million.

4 brokerages have issued 1-year price objectives for Endologix's stock. Their forecasts range from $1.00 to $7.00. On average, they anticipate Endologix's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 444.7% from the stock's current price. View Analyst Price Targets for Endologix.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endologix.

News articles about ELGX stock have been trending positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Endologix earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Endologix.

Some companies that are related to Endologix include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), Anika Therapeutics (ANIK), Antares Pharma (ATRS) and OraSure Technologies (OSUR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Endologix investors own include CA (CA), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Och-Ziff Capital Management Group (OZM), Gran Tierra Energy (GTE), Belden (BDC) and Precision Drilling (PD).

Endologix's stock is owned by a number of of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (18.76%), Renaissance Technologies LLC (4.21%), Oxford Asset Management LLP (1.50%), Jacobs Levy Equity Management Inc. (1.38%), Partner Fund Management L.P. (0.89%) and New York State Common Retirement Fund (0.63%). Company insiders that own Endologix stock include Christopher G Chavez, Gregory D Waller, John Onopchenko, Thomas F Zenty III, Thomas Wilder and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.

ELGX stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Partner Fund Management L.P., Oxford Asset Management LLP, Alambic Investment Management L.P. and Spark Investment Management LLC. Company insiders that have sold Endologix company stock in the last year include Gregory D Waller and Thomas Wilder. View Insider Buying and Selling for Endologix.

ELGX stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., ArrowMark Colorado Holdings LLC, Renaissance Technologies LLC and Perkins Capital Management Inc.. Company insiders that have bought Endologix stock in the last two years include John Onopchenko, Thomas F Zenty III and Vaseem Mahboob. View Insider Buying and Selling for Endologix.

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ELGX stock can currently be purchased for approximately $0.83.

Endologix has a market capitalization of $14.82 million and generates $143.37 million in revenue each year. The medical instruments supplier earns $-79,710,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Endologix employs 528 workers across the globe.View Additional Information About Endologix.

The official website for Endologix is http://www.endologix.com/.

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]